Featured Research

from universities, journals, and other organizations

Sweet defence against lethal bacteria: Synthesizing a potential vaccine candidate for an antibiotic-resistant pathogen

Date:
May 31, 2011
Source:
Max-Planck-Gesellschaft
Summary:
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals. The sugar-based vaccine elicited a specific and effective immune response in mice. Moreover, the scientists have also discovered strong indications that the substance can stimulate the human immune system to form antibodies against the bacterium.

Stimulating the immune system: on the basis of a hexasaccharide, scientists from Potsdam developed a vaccine against the Clostridium difficile bacterium, which causes severe gastrointestinal diseases in hospitals.
Credit: © MPI of Colloids and Interfaces

There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals. The sugar-based vaccine elicited a specific and effective immune response in mice. Moreover, the scientists have also discovered strong indications that the substance can stimulate the human immune system to form antibodies against the bacterium.

Clostridium difficile bacterium can turn into a life-threatening condition: a highly virulent and antibiotic-resistant strain of the spore-forming pathogen Clostridium difficile bacterium appeared in the USA and certain Western European countries some eight years ago. Since then it has been posing a major risk for hospitalised patients, in particular, who are being treated with antibiotics or have a weak immune system, such as cancer or HIV patients. Whereas no more than four per cent of healthy humans have C. difficile in their gastrointestinal system, the bacterium colonises the intestines of 20 to 40 per cent of hospitalised patients. If other bacteria in the intestinal flora are repressed by antibiotics, the rod-shaped bacterium can reproduce extremely fast. It produces toxins which cause diarrhea and gastrointestinal inflammation, often with a lethal outcome. Surviving patients require a very costly aftercare. This new, highly virulent pathogen can produce around 20 times more toxins and significantly more spores than previously identified pathogens.

However, a carbohydrate in the bacterial cell wall now provides the team of scientists led by Peter H. Seeberger at the Max Planck Institute of Colloids and Interfaces in Potsdam a "point of attack" for a potential vaccine. "Initial testing of the sugar-based antigen synthesised by the team has already produced very promising results," says Peter H. Seeberger, Director at the Max Planck Institute in Potsdam.

The chemists in the team first developed a synthesis for the essential component of the antigen: the hexasaccharide. To assemble the oligosaccharide, they used four different monosaccharide building blocks. An efficient and convergent approach created the exact molecule with the required arrangement of the monosaccharides. "Synthesizing complex polysaccharides is still a challenge, not least because sugar molecules can bind in several different places," Peter H. Seeberger says. However, the chemists were able to block other reaction sites so that they could exactly control where the original saccharides bound.

The scientists then conjugated the hexasaccharide to the CRM 197 protein, which is used in many vaccines, as sugar alone, as antigen, does not elicit an effective immune response. In order to defend itself successfully against a C. difficile infection, the immune system must also use another antigen. The chemical glycoprotein conjugate triggered a very effective immune response in two mice which were injected with the substance three times, at 2-week intervals. "The fact that mice are producing antibodies against the carbohydrates is in itself a success," Peter H. Seeberger says. "Not all carbohydrates trigger the production of antibodies." Furthermore, the antibodies produced by the mice bound exclusively to the sugar. Thus, the antigen cannot cause an autoimmune disease.

Additionally, the scientists proved that the antibodies developed against the hexasaccharide are also part of the human immune response; in the stool of hospital patients infected with C. difficile, they found antibodies against the sugar. "We can therefore expect to see that the human immune system produces antibodies against the sugar when vaccinated," Seeberger concludes. What is more, "since the natural sugar already elicits the production of a small number of antibodies, we hope that the synthetic glycoprotein conjugate will trigger a more effective response."

The vaccine candidate must now be subjected to further testing. First, it must be established whether it can effectively prevent infection in animals. "If these tests are successful, it will probably still take one or two years before the vaccine is tested on humans," explains Peter H. Seeberger.

The vaccine candidate against C. difficile does not contain the only immunologically effective sugar from Seeberger's laboratory. Together with his colleagues, the chemist is developing sugar-based vaccines against numerous pathogens. "The current work is therefore also a proof of the progress made in glycochemistry and glycobiology," according to Seeberger, who was awarded the 2007 Körber European Science Award for his development of a sugar synthesiser. The number of biological sugar molecules that can be produced by chemists in the laboratory is on the increase, which gives the biologists and medical scientists the opportunity to investigate their specific impacts. This fills Peter H. Seeberger with optimism: "These advances will lead to quantum leaps in related research areas, such as immunology, biology and medicine."


Story Source:

The above story is based on materials provided by Max-Planck-Gesellschaft. Note: Materials may be edited for content and length.


Journal Reference:

  1. Matthias A. Oberli, Marie-Lyn Hecht, Pascal Bindschädler, Alexander Adibekian, Thomas Adam, Peter H. Seeberger. A Possible Oligosaccharide-Conjugate Vaccine Candidate for Clostridium difficile Is Antigenic and Immunogenic. Chemistry & Biology, 2011; 18 (5): 580 DOI: 10.1016/j.chembiol.2011.03.009

Cite This Page:

Max-Planck-Gesellschaft. "Sweet defence against lethal bacteria: Synthesizing a potential vaccine candidate for an antibiotic-resistant pathogen." ScienceDaily. ScienceDaily, 31 May 2011. <www.sciencedaily.com/releases/2011/05/110530080405.htm>.
Max-Planck-Gesellschaft. (2011, May 31). Sweet defence against lethal bacteria: Synthesizing a potential vaccine candidate for an antibiotic-resistant pathogen. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2011/05/110530080405.htm
Max-Planck-Gesellschaft. "Sweet defence against lethal bacteria: Synthesizing a potential vaccine candidate for an antibiotic-resistant pathogen." ScienceDaily. www.sciencedaily.com/releases/2011/05/110530080405.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) — The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) — Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins